UK community pharmacy reimbursement reform points to Drug Tariff and specials supply changes

Who is this relevant for?

• Pharmaceutical buyers sourcing shortage medicines
• Hospitals managing supply risk
• Manufacturers evaluating UK market entry
• Distributors monitoring sourcing opportunities

The Department of Health and Social Care has closed the first phase of its consultation on community pharmacy reimbursement reform in England and will take all proposals into detailed discussion with the Pharmaceutical Services Negotiating Committee.

That matters because the response keeps open changes that could alter how Drug Tariff prices are set, how medicine margin is distributed, and how specials procurement is handled. For operators across the supply chain, the signal is not that reform is settled. It is that the government still sees enough merit in every proposal to move them forward.

The consultation covered eight proposals. According to the response, most received majority support. Two areas drew weaker backing: Category C reimbursement and specials procurement. The government says the disagreement was not significant given the number of respondents who selected "do not know", and it will still progress both areas.

What the response says on Category A pricing

The clearest operational detail in the published response concerns Category A generic medicines.

Today, Category A reimbursement prices in Part VIIIA of the Drug Tariff are based on weighted manufacturer and wholesaler list prices. The department says those lists do not always reflect the prices pharmacy contractors pay. It also cites cases where suppliers use multiple price lists, do not publish price lists, or use the Drug Tariff price itself as a list price.

In the department’s view, that can leave reimbursement prices materially above actual selling prices. The stated consequences are practical:

• margin is found retrospectively through the margin survey
• later downward adjustments can affect contractor cash flow
• some contractors retain more margin than others depending on product mix
• inflated reimbursement prices may affect how medicines appear on cost effectiveness grounds

The proposed reform is to use actual purchase, sales and volume data already collected under the Health Service Products (Provision and Disclosure of Information) Regulations 2018 to set Category A reimbursement prices. Those prices would still include an element of medicine margin.

For pharmacy operators, the point is straightforward. The department wants Category A reimbursement to track real market prices more closely and rely less on retrospective correction. It also says Category A would remain separate from Category M, and that it does not plan to use Category A to make medicine margin adjustments under the Community Pharmacy Contractual Framework.

That distinction matters for suppliers and contractors dealing in lower-volume generics. The response acknowledges that Category A products often have lower volumes and more limited competition than Category M lines.

Why the second phase matters

The government is explicit that this first consultation was on high-level principles. The mechanics are still to be discussed with PSNC, and the response says that does not mean every proposal will be implemented or delivered on the same timetable.

That leaves a period of uncertainty for companies whose pricing, contracting, and reimbursement assumptions depend on current Drug Tariff methods. The policy direction is visible, but the operating detail is still unresolved.

For manufacturers and distributors, that means watching for any change in how supplier data feeds reimbursement setting. For buyers and providers managing medicine access, it means keeping an eye on proposals that could affect specials procurement alongside tariff-based reimbursement.

Specials remain in scope

The response gives limited detail in the published summary excerpt, but one point is clear: specials procurement remains under active consideration despite mixed consultation support.

That keeps attention on unlicensed medicine supply. Any change to procurement arrangements in this area can affect how products are sourced and reimbursed through community pharmacy channels. The government has not settled the final model in this response, but it has confirmed that the proposal will move into detailed discussion rather than being dropped.

For the market, the immediate takeaway is procedural rather than final. Reform is still live across both tariff pricing and specials procurement, and the next phase will determine how far the government turns consultation principles into operating rules.